Xenetic Biosciences, Inc.

menu

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Technology
    • Overview
    • DNase Platform
    • XCART™ Platform
    • PolyXen®
    • Publications
  • Product Pipeline
    • Overview
    • DNase
    • XCART™
    • PolyXen®
  • News & Media
    • Press Releases
    • Presentations
    • Multimedia
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations
  • Multimedia

Press Releases

  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences Announces Full Year 2013 Financial Results and Business Update

Apr 16, 2014

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis

Apr 7, 2014

Xenetic Biosciences Appoints Darlene Deptula-Hicks to Board of Directors

Apr 4, 2014

Xenetic Biosciences Announces Opening of Corporate Headquarters and R&D Facility in Lexington, MA

Mar 4, 2014

Xenetic Biosciences Announces Ticker Symbol Change to XBIO

Feb 14, 2014

  • « Previous
  • 1...
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2023Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap